Ruth Oren Hommonai
Chief Executive Officer chez INTER GAMMA INVESTMENT COMPANY LTD
Profil
Ruth Oren Hommonai is currently the Chief Executive Officer at Inter-Gamma Investment Ltd.
She previously worked as the Director of the Legal Department at Dexcel Pharma Technologies Ltd.
Ms. Oren Hommonai graduated from Tel-Aviv University and holds an MBA from The Interdisciplinary Center Herzliya.
Postes actifs de Ruth Oren Hommonai
| Sociétés | Poste | Début |
|---|---|---|
| INTER GAMMA INVESTMENT COMPANY LTD | Chief Executive Officer | 01/01/2014 |
Anciens postes connus de Ruth Oren Hommonai
| Sociétés | Poste | Fin |
|---|---|---|
Dexcel Pharma Technologies Ltd.
 Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | General Counsel | - |
Formation de Ruth Oren Hommonai
| Tel-Aviv University | Graduate Degree |
| The Interdisciplinary Center Herzliya | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTER GAMMA INVESTMENT COMPANY LTD | Finance |
| Entreprise privées | 1 |
|---|---|
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | Health Technology |
